CardioDx, which sells a diagnostic test for coronary artery disease, withdrew its plans for an initial public offering on Tuesday citing the terms currently obtainable in the public marketplace were not sufficiently attractive to warrant proceeding with the public offering. The company had initially planned to raise $75 million by offering 5.0 million shares at a range of $14 to $16 in November 2013 IPO before it postponed its deal. It later revived its IPO filing in late April.
Help employers find you! Check out all the jobs and post your resume.
